Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 159

Related Articles by Review for PubMed (Select 18401416)

1.

Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.

Hochhaus A, Baccarani M, Deininger M, Apperley JF, Lipton JH, Goldberg SL, Corm S, Shah NP, Cervantes F, Silver RT, Niederwieser D, Stone RM, Dombret H, Larson RA, Roy L, Hughes T, Müller MC, Ezzeddine R, Countouriotis AM, Kantarjian HM.

Leukemia. 2008 Jun;22(6):1200-6. doi: 10.1038/leu.2008.84. Epub 2008 Apr 10.

PMID:
18401416
2.
3.

Dasatinib: a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia.

McCormack PL, Keam SJ.

Drugs. 2011 Sep 10;71(13):1771-95. doi: 10.2165/11207580-000000000-00000. Review.

PMID:
21902298
5.

Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase.

Kantarjian HM, Cortes J, La Rosée P, Hochhaus A.

Cancer. 2010 Mar 15;116(6):1419-30. doi: 10.1002/cncr.24928. Review.

6.

Targeted chronic myeloid leukemia therapy: Seeking a cure.

Fausel C.

Am J Health Syst Pharm. 2007 Dec 15;64(24 Suppl 15):S9-15. Review.

PMID:
18056932
7.

Improving frontline treatment for chronic myeloid leukemia: emerging evidence for use of nilotinib and dasatinib.

Erba HP, Pham DC, Zaiden R, Vu H, Tai S.

Clin Adv Hematol Oncol. 2011 Oct;9(10):734-45. Review.

PMID:
22252576
8.

Treatment options for patients with chronic myeloid leukemia who are resistant to or unable to tolerate imatinib.

Stein B, Smith BD.

Clin Ther. 2010 May;32(5):804-20. doi: 10.1016/j.clinthera.2010.05.003. Review.

9.

Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: a systematic review and economic evaluation.

Rogers G, Hoyle M, Thompson Coon J, Moxham T, Liu Z, Pitt M, Stein K.

Health Technol Assess. 2012;16(22):1-410. doi: 10.3310/hta16220. Review.

10.

Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia.

Deremer DL, Ustun C, Natarajan K.

Clin Ther. 2008 Nov;30(11):1956-75. doi: 10.1016/j.clinthera.2008.11.014. Review.

PMID:
19108785
11.

Therapy options in imatinib failures.

Ramirez P, DiPersio JF.

Oncologist. 2008 Apr;13(4):424-34. doi: 10.1634/theoncologist.2007-0170. Review.

12.

Bosutinib: a review of its use in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.

Syed YY, McCormack PL, Plosker GL.

BioDrugs. 2014 Feb;28(1):107-20. doi: 10.1007/s40259-013-0082-x. Review.

PMID:
24420842
13.

Activity and safety of dasatinib as second-line treatment or in newly diagnosed chronic phase chronic myeloid leukemia patients.

Breccia M, Alimena G.

BioDrugs. 2011 Jun 1;25(3):147-57. doi: 10.2165/11591840-000000000-00000. Review.

PMID:
21528941
14.

[Research advance on molecular genetics of CML blast crisis].

Zhu HQ, Zhang S, Liu XL.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008 Feb;16(1):217-21. Review. Chinese.

PMID:
18315935
15.

Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses.

Pavey T, Hoyle M, Ciani O, Crathorne L, Jones-Hughes T, Cooper C, Osipenko L, Venkatachalam M, Rudin C, Ukoumunne O, Garside R, Anderson R.

Health Technol Assess. 2012;16(42):iii-iv, 1-277. doi: 10.3310/hta16420. Review.

16.
17.

Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a 'head-to-head comparison'.

Rosti G, Castagnetti F, Gugliotta G, Palandri F, Martinelli G, Baccarani M.

Leuk Lymphoma. 2010 Apr;51(4):583-91. doi: 10.3109/10428191003637282. Review.

PMID:
20302388
18.
19.

Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias.

Jabbour E, Cortes J, Kantarjian H.

Expert Opin Investig Drugs. 2007 May;16(5):679-87. Review. Erratum in: Expert Opin Investig Drugs. 2007 Jul;16(7):1135.

PMID:
17461740
20.

Management of Bcr-Abl-positive leukemias with dasatinib.

Hochhaus A.

Expert Rev Anticancer Ther. 2007 Nov;7(11):1529-36. Review.

PMID:
18020922
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk